Pulmonary Cell News Volume 10.24 | Jun 24 2021

    By
    Justin.choi
    -
    0
    38






    2021-06-24 | PULCN 10.24


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 10.24 – 24 June, 2021
    TOP STORY

    Multi-Omic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation

    Scientists identified genomic contexts in which neuroendocrine transformation was favored, including frequent loss of the 3p chromosome arm.
    [Cancer Discovery]

    Abstract

    Your cultureware impacts your ALI cultures - Learn more about using Transwell inserts >
    PUBLICATIONSRanked by the impact factor of the journal

    Pretreatment with Valproic Acid Alleviates Pulmonary Fibrosis through Epithelial–Mesenchymal Transition Inhibition In Vitro and In Vivo

    In vitro, epithelial-mesenchymal transition (EMT) was induced by the administration of transforming growth factor-β1 in a human alveolar epithelial cell line.
    [Laboratory Investigation]

    Full Article

    Autophagy of Mucin Granules Contributes to Resolution of Airway Mucous Metaplasia

    Researchers hypothesized that the autophagy pathway was required for resolution of mucous metaplasia by eliminating excess non-secreted intracellular mucin granules.
    [Scientific Reports]

    Full Article

    Interactions of Nasal Epithelium with Macrophages and Dendritic Cells Variously Alter Urban PM-Induced Inflammation in Healthy, Asthma and COPD

    Scientists characterized the immune processes induced by the epithelium after urban particulate matter exposure in special regard to interactions with monocyte-derived dendritic cells and monocyte-derived macrophages in obstructive lung diseases.
    [Scientific Reports]

    Full Article

    Notch Signaling and Efficacy of PD-1/PD-L1 Blockade in Relapsed Small Cell Lung Cancer

    To identify predictors of clinical benefit to immune checkpoint blockade, investigators performed immunogenomic profiling of tumor samples from patients with relapsed small cell lung cancer.
    [Nature Communications]

    Full Article

    ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling-Driven Epithelial-Mesenchymal Transition

    Researchers found that high expression of α-enolase was present in metastatic lung cancer cell lines and malignant tumors and was associated with poor overall survival of lung cancer patients.
    [Cancer Research]

    Abstract

    Comprehensive Molecular Profiling of Pulmonary Pleomorphic Carcinoma

    Scientists performed next-generation sequencing to determine the genomic and transcriptomic profiles of pulmonary pleomorphic carcinoma (PPC). They sequenced the DNAs and RNAs of 78 specimens from 52 patients with PPC.
    [npj Precision Oncology]

    Full Article

    Targeting Therapy-Resistant Lung Cancer Stem Cells via Disruption of the AKT/TSPYL5/PTEN Positive-Feedback Loop

    Researchers identified testis-specific Y-like protein 5 (TSPYL5) as an upstream regulator of Cancer stem cells (CSC)-associated genes in non-small cell lung cancer cells, and suggested as a therapeutic target for CSC elimination.
    [Communications Biology]

    Full Article

    TGF-β-Dependent Reprogramming of Amino Acid Metabolism Induces Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancers

    Investigators showed that TGF-β induced reprogramming of intracellular amino acid metabolism, which was necessary to promote epithelial–mesenchymal transition in non-small cell lung cancer cells.
    [Communications Biology]

    Full Article

    Optimizing in vitro lung models with Dr. Rachael Rayner.
    REVIEWS

    Selecting the Optimal Immunotherapy Regimen in Driver-Negative Metastatic NSCLC

    The authors discuss the current treatment landscape and detail their approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.
    [Nature Reviews Clinical Oncology]

    Abstract

    INDUSTRY AND POLICY NEWS

    Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 Mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States

    Teva Pharmaceuticals, Ltd. announced its US launch of the first generic version of twice daily PERFOROMIST®,formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
    [Teva Pharmaceuticals, Ltd.]

    Press Release

    FEATURED EVENT

    EMBO Workshop: Long-Distance Cell-Cell Signaling in Development and Disease

    September 5 – 8, 2021
    Exeter, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Lung Immunology

    Stanford School of Medicine – Palo Alto, California, United States

    Postdoctoral Fellow – In-Situ Gene Therapy

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Fellow – Cancer Biology and Signaling

    H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States

    Post-Doctoral Fellow – Lung Diseases

    University of Pennsylvania and Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States

    Post-Doctoral Scholar – Lung or Pancreatic Cancer

    University of California San Francisco – San Francisco, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter